AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 232 min read$BCPC

Balchem Corp (BCPC) Q3 2026 Earnings Call Highlights: Record Revenue, 29th Straight

Balchem Corp (BCPC) reported Q3 2026 record revenue of $291M, up 8.6%, with all segments growing. EBITDA rose 12.4% to $80M, marking 29 straight quarters of growth. The company faces inflationary pressures and seasonality challenges but expects year-over-year growth in Q4. Inventory increased to $177M due to inflation and growth. Clinical trials in Alzheimer's and cardiovascular health show promise, with marketing efforts planned. BCPC's effective tax rate is expected to be 22.5-23%.

Original reporting
finance.yahoo.com
Published Oct 23, 2026, 11:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 23, 2026, 11:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Balchem Corp (BCPC) Q3 2026 Earnings Call Highlights: Record Revenue, 29th Straight — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$BCPCNeutralMed
01

Why it matters

The earnings beat provides fresh data for valuation models, while the guidance of a sequential Q4 decline may temper enthusiasm.

02

Market read

Earnings release is material for investors; the record Q3 performance may drive short-term price movement, while inventory and cost pressures could influence longer-term sentiment.

03

What to watch

Potential upside from upcoming product launches and new encapsulated methionine rollout in Q4.

Relevance 8/10Novelty 8/10Timing: post-earnings release today

Background

Balchem's Q3 2026 earnings call highlighted record sales, earnings, and margin expansion across segments, with commentary on inflation, inventory, and seasonal outlook.

Company-level read

Ticker impact

$BCPCNeutralHigh confidence
Context

Q3 2026 earnings call disclosed record revenue, earnings and margin expansion, plus inventory buildup and seasonal Q4 outlook.

Expected impact

potential modest upside on Q3 beat, offset by near-term downside pressure from seasonal Q4 guidance

Evidence & confidence

New earnings numbers are material and not previously public; investors will reassess valuation based on growth and margin trends.

Market effects

Sector

Strong performance may lift the specialty chemicals and nutrition sectors.

Regional

Positive U.S. results could boost peer stocks in the animal and human nutrition space.

Global

Limited; impact confined to niche nutrition chemicals market.

Counterpoint

What could challenge this read

Investors may focus on inventory buildup and inflationary cost pressures, questioning sustainability of margins.

Key entities

  • Company
    Balchem Corp

    Specialty chemicals and nutrition products manufacturer.

  • Executive
    Ted Harris

    CEO of Balchem, discussed trial updates and growth strategy.

  • Executive
    Martin Bengtsson

    CFO of Balchem, provided financial details and outlook.

Read at source← All news

StoryBalchem reports record Q3 2026 sales, earnings and 29th straight EBITDA growth

Also covered by

4 outlets

Related articles

OCT 23
$BCPCHigh

Balchem (BCPC) Q3 2026 Earnings Call Transcript

Balchem (BCPC) reported Q3 2026 record revenue of $291M, up 8.6% YoY, with GAAP net income of $47M, up 16%. Growth was driven by all three segments: Human Nutrition, Animal Nutrition, and Specialty Products. The company highlighted positive studies on VitaCholine and K2VITAL DELTA, supporting long-term growth prospects. Balchem repurchased $28M of stock and reduced borrowings by $28M, maintaining a net leverage ratio of 0.2x.

finance.yahoo.com2 min
OCT 23
$BCPCHigh

Balchem beats Q3 estimates on strong segment growth

Balchem Corporation (NASDAQ:BCPC) reported Q3 adjusted EPS of $1.57, beating estimates of $1.43. Revenue was $290.7M, up 8.6% YoY. All segments showed growth, with Human Nutrition sales at $188.2M, Animal Nutrition at $63.0M, and Specialty Products at $37.3M. Gross margin improved to 36.4%. The company repurchased $28M in stock during the quarter.

investing.com2 min
OCT 23
$BCPCMed

Balchem Corporation Reports Third Quarter 2026 Financial Results

BALCHEM CORP (BCPC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Human Nutrition & Health | Animal Nutrition & Health | Specialty Products Balchem Corporation Reports Third Quarter 2026 Financial Results Montvale, NJ, October 23, 2026 - Balchem Corporation (NASDAQ: BCPC) today reported financial results for its 2026 fiscal third q

SEC EDGAR 8-K2 min